ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG VÀ KẾT QUẢ ĐIỀU TRỊ TÂN BỔ TRỢ Ở NGƯỜI BỆNH UNG THƯ VÚ CÓ HER2 (+) TẠI BỆNH VIỆN K

Abstract

Objective: To describe the clinical and clinicopathologic characteristics and evaluate outcomes of neoadjuvant chemotherapy combined with anti-HER2 therapy in patients with HER2-positive breast cancer who did not undergo immediate surgery. Methods: We conducted a retrospective–prospective observational cohort of 70 patients treated with neoadjuvant chemotherapy plus anti-HER2 agents at K Hospital, Quan Su campus, from January 2021 to December 2024. Results: Of 70 patients, 48.57% had primary operable early-stage disease. Chemotherapy combined with trastuzumab with or without pertuzumab was administered in 74.29% and 25.71%, respectively. Clinical response was achieved in 98.06% of patients. The pathological complete response (pCR; Chevallier 1–2) rate was 53.85% with trastuzumab and 77.78% with the trastuzumab–pertuzumab doublet. All patients proceeded to surgery after neoadjuvant therapy, including five oncoplastic procedures and one breast-conserving surgery. Hematologic adverse events were predominantly grade 0–1 (55.7%); alopecia and fatigue were most frequent. A ≥10% decline in LVEF occurred in several cases, mostly mild and reversible; one patient discontinued due to cardiotoxicity. Conclusion: Adding anti-HER2 therapy to neoadjuvant chemotherapy markedly increased pCR rates, facilitated downstaging, and improved the likelihood of curative and breast-conserving surgery, particularly with the trastuzumab–pertuzumab combination.